Evidence map›Paper›PMID 26459286›Full record

ArticleBMC cancer2015

Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.

Rishabh Kala, Harsh N Shah, Samantha L Martin, Trygve O Tollefsbol

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 1 synthesis or guideline pooled it, 156 citations in OpenAlex.

  1. Naturally Available Extracts Inhibiting Cancer Progression: A Systematic Review.Journal of evidence-based complementary & alternative medicine · 2017
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rishabh KalaDepartment of Biology, University of Alabama at Birmingham, 1300 University Boulevard, Birmingham, AL, 35294, USA. rishabh@uab.edu.
Harsh N ShahDepartment of Biology, University of Alabama at Birmingham, 1300 University Boulevard, Birmingham, AL, 35294, USA. hnshah@uab.edu.
Samantha L MartinDepartment of Biology, University of Alabama at Birmingham, 1300 University Boulevard, Birmingham, AL, 35294, USA. jcvessel@uab.edu.
Trygve O TollefsbolDepartment of Biology, University of Alabama at Birmingham, 1300 University Boulevard, Birmingham, AL, 35294, USA. trygve@uab.edu.
University of Alabama at Birmingham · US

Funding

Combinatorial epigenetic-based prevention of breast cancerR01CA178441 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TOLLEFSBOL, TRYGVE O · 2014 to 2025
$3.2M
NCI NIH HHS R01 CA178441NCI NIH HHS R0I CA178441
6 · The paper itself

Abstract

backgroundNutrition is believed to be a primary contributor in regulating gene expression by affecting epigenetic pathways such as DNA methylation and histone modification. Resveratrol and pterostilbene are phytoalexins produced by plants as part of their defense system. These two bioactive compounds when used alone have been shown to alter genetic and epigenetic profiles of tumor cells, but the concentrations employed in various studies often far exceed physiologically achievable doses. Triple-negative breast cancer (TNBC) is an often fatal condition that may be prevented or treated through novel dietary-based approaches.

methodsHCC1806 and MDA-MB-157 breast cancer cells were used as TNBC cell lines in this study. MCF10A cells were used as control breast epithelial cells to determine the safety of this dietary regimen. CompuSyn software was used to determine the combination index (CI) for drug combinations.

resultsCombinatorial resveratrol and pterostilbene administered at close to physiologically relevant doses resulted in synergistic (CI <1) growth inhibition of TNBCs. SIRT1, a type III histone deacetylase (HDAC), was down-regulated in response to this combinatorial treatment. We further explored the effects of this novel combinatorial approach on DNA damage response by monitoring γ-H2AX and telomerase expression. With combination of these two compounds there was a significant decrease in these two proteins which might further resulted in significant growth inhibition, apoptosis and cell cycle arrest in HCC1806 and MDA-MB-157 breast cancer cells, while there was no significant effect on cellular viability, colony forming potential, morphology or apoptosis in control MCF10A breast epithelial cells. SIRT1 knockdown reproduced the effects of combinatorial resveratrol and pterostilbene-induced SIRT1 down-regulation through inhibition of both telomerase activity and γ-H2AX expression in HCC1806 breast cancer cells. As a part of the repair mechanisms and role of SIRT1 in recruiting DNMTs, the effects of this combination treatment was also explored on DNA methyltransferases (DNMTs) expression. Interestingly, the compounds resulted in a significant down-regulation of DNMT enzymes with no significant effects on DNMT enzyme expression in MCF10A control cells.

conclusionCollectively, these results provide new insights into the epigenetic mechanisms of a novel combinatorial nutrient control strategy that exhibits synergy and may contribute to future recalcitrant TNBC prevention and/or therapy.

Indexed as

DNA DamageEpigenesis, GeneticGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell Cycle CheckpointsCell Line, TumorCell SurvivalDNA (Cytosine-5-)-MethyltransferasesDose-Response Relationship, DrugDrug SynergismEnzyme ActivationErb-b2 Receptor Tyrosine KinasesFemaleGene Knockdown TechniquesDNA (Cytosine-5-)-MethyltransferasesErb-b2 Receptor Tyrosine KinasesHistonespterostilbeneResveratrolSirtuin 1StilbenesTelomerase

Identifiers

PMID26459286
PMCPMC4603342
OpenAlexW1948125805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.